S. Kung

2 papers in the library · 78 citations · publishing 2023

Papers

Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study.

Journal of Clinical Psychiatry February 1, 2023 Balwinder Singh, S. Kung, Vanessa K. Pazdernik et al. 64 citations

In adults with treatment-resistant depression, intravenous (IV) ketamine and intranasal (IN) esketamine produced similar rates of symptom improvement and remission, but remission was reached in fewer treatment sessions with IV ketamine. Over up to six IV or eight IN treatments, depressive symptoms were measured before and 24 hours after each session. Among 62 participants (median age 50, 65% female), neither the change in symptom scores nor the proportion achieving response or remission differed significantly between groups. However, time to remission—adjusting for age, sex, body mass index, and baseline severity—was five times faster with IV ketamine than with IN esketamine. A randomized controlled trial is needed to confirm these results.

DOI: 10.4088/jcp.22m14548 Medicine

Efficacy of Ketamine with and without Lamotrigine in Treatment-Resistant Depression: A Preliminary Report

Pharmaceuticals August 1, 2023 B. Joseph, N. Nuñez, S. Kung et al. 14 citations

For adults with treatment-resistant depression, taking lamotrigine alongside intravenous ketamine or intranasal esketamine does not significantly reduce the antidepressant effect of the treatments. In a historical cohort study, response and remission rates were similar whether patients were on lamotrigine or not. There was a trend toward lower dissociation scores among those taking lamotrigine, especially with IV ketamine. The study was limited by only 13 patients on lamotrigine, so the evidence is insufficient to conclude that lamotrigine attenuates the antidepressant effect, but it may reduce dissociation.

DOI: 10.3390/ph16081164 Full text Medicine